e-learning
resources
Munich 2014
Sunday, 07.09.2014
Improving diagnosis of thoracic tumours
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Role of mean sUV and metabolic tumor volume by PET/CT for determination of mean survival time in patients with non-small cell lung cancer
E. Kurtipek, M. çayci, N. Düzgün, H. Esme, S. Baktik, M. S. Aygün, Y. Ünlü, C. Burnik, T. T. Bekçi, Y. Terzi (Konya, Samsun, Turkey)
Source:
International Congress 2014 – Improving diagnosis of thoracic tumours
Session:
Improving diagnosis of thoracic tumours
Session type:
Poster Discussion
Number:
347
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
E. Kurtipek, M. çayci, N. Düzgün, H. Esme, S. Baktik, M. S. Aygün, Y. Ünlü, C. Burnik, T. T. Bekçi, Y. Terzi (Konya, Samsun, Turkey). Role of mean sUV and metabolic tumor volume by PET/CT for determination of mean survival time in patients with non-small cell lung cancer. Eur Respir J 2014; 44: Suppl. 58, 347
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Imaging of complicated pneumonia: what is new?
Panel discussion: ICU admission of lung cancer patients – Is COVID-19 a game-changer?
Imaging of eosinophilic lung disease
Related content which might interest you:
The prognostic value of the tumor shrinkage rate for progression-free survival in patients with non-small cell lung cancer receiving gefitinib
Source: International Congress 2014 – Advances in diagnosis and therapy of thoracic tumours
Year: 2014
Algorithm of preoperative N-staging of non-small cell lung cancer
Source: Annual Congress 2013 –Oncological thoracic surgery
Year: 2013
Prognostic value of preoperative C-reactive protein in resectable non-small cell lung cancer - 5-years prospective study
Source: International Congress 2014 – Diagnosis, imaging and surgery for thoracic tumours
Year: 2014
Comparing performance and cost of EBUS-TBNA versus other methods for diagnosis and staging of non-small cell lung cancer (NSCLC)
Source: International Congress 2014 – Improving diagnosis of thoracic tumours
Year: 2014
Impact of second-line treatment on overall survival of advanced lung adenocarcinoma patients
Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up
Year: 2016
Preoperative FDG uptake on PET/CT predicts disease recurrence and survival in early stage non-small cell lung cancer (NSCLC)
Source: International Congress 2016 – Clinical aspects of lung cancer
Year: 2016
Safety and efficacy of erlotinib in patients with squamous cell lung cancer
Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series
Year: 2014
Screening for intracerebral metastasis in radically treated non-small cell lung cancer patients
Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up
Year: 2016
Evaluation of predictive and therapeutic value of WSX1/IL27 axis in non-small cell lung cancer (NSCLC)
Source: International Congress 2015 – Cell biology of lung cancer and new biomarkers
Year: 2015
Prognostic factors for survival in lung cancer
Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer
Year: 2013
Should preoperative FDG uptake on PET/CT guide postoperative surveillance in surgical non-small cell lung cancer (NSCLC)
Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up
Year: 2016
Locoregional recurrence after pulmonary segmentectomy of non-small cell lung cancer
Source: Annual Congress 2013 –Oncological thoracic surgery
Year: 2013
Clinical profile and survival of patients undergoing surgery for non-small cell lung cancer: Impact of positron emission tomography adoption
Source: International Congress 2014 – Diagnosis, imaging and surgery for thoracic tumours
Year: 2014
EBUS-TBNA for nodal restaging and relapse in lung cancer
Source: International Congress 2014 – Diagnosis, imaging and surgery for thoracic tumours
Year: 2014
Stereotactic body radiation does not impair respiratory health in patients with stage I non-small cell lung cancer
Source: Annual Congress 2013 –Lung cancer resection and radiotherapy and thoracic oncology late breaking abstracts
Year: 2013
CD33
+
CD14
-
CD11b
+
CD66b
+
CD15
+
VEGFR-1
hi
myeloid derived suppressor cells and their clinical relevance in non-small cell lung cancer
Source: International Congress 2014 – Biology and pathology of thoracic tumours
Year: 2014
Neutrophil/lymphocyte ratio as a prognostic marker for curative-intent surgery in non-small cell lung cancer
Source: International Congress 2015 – Surgery and lung cancer: results and complications
Year: 2015
Advanced lung cancer inflammation index (ALI): A new pronostic score in patients with non small cell lung cancer
Source: International Congress 2016 – Lung cancer and immune cells: friends or foes?
Year: 2016
The role of second line chemotherapy in small cell lung cancer: A retrospective analysis
Source: Annual Congress 2013 –Advances in the therapy of lung cancer
Year: 2013
Surgical treatment outcomes on early-stages of non-small-cell lung cancer
Source: International Congress 2015 – Diagnosis and therapy of lung cancer
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept